This study is in progress, not accepting new patients
Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCSF
- Dates
- study startedcompletion around
- Principal Investigator
- by Michael J Peluso, MD (ucsf)
Description
Summary
Official Title
Details
Keywords
Eligibility
Location
Lead Scientist at University of California Health
- Michael J Peluso, MD (ucsf)
I am an infectious disease clinician and researcher. My primary interests are HIV cure and Long COVID. For HIV, I am involved with clinical and laboratory research aimed at understanding the HIV reservoir and implementing clinical trials to disrupt the reservoir with the aim of inducing antiretroviral therapy-free HIV remission.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Michael Peluso, MD
- ID
- NCT05877508
- Phase
- Phase 2 COVID-19 Research Study
- Study Type
- Interventional
- Participants
- Expecting 30 study participants
- Last Updated